Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.
D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D010525:Peripheral Nerves / Q000187:drug effects; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D003907:Dexamethasone; D001215:Asparaginase; D011241:Prednisone